Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4605674)

Published in PLoS One on October 14, 2015

Authors

Daniel D Murray1, Kazuo Suzuki1, Matthew Law1, Jonel Trebicka2, Jacquie Neuhaus3, Deborah Wentworth3, Margaret Johnson4, Michael J Vjecha5, Anthony D Kelleher1, Sean Emery1, INSIGHT ESPRIT and SMART Study Groups

Author Affiliations

1: The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia.
2: Department of Internal Medicine, University of Bonn, Bonn, Germany.
3: University of Minnesota, Minneapolis, Minnesota, United States of America.
4: Ian Charleson Day Centre, Royal Free Hampstead NHS Trust, London, United Kingdom.
5: Institute for Clinical Research, Veterans Affairs Medical Center, Washington D.C., United States of America.

Associated clinical trials:

A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study) | NCT00027352

An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy (ESPRIT) | NCT00004978

Articles cited by this

CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72

Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 10.56

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09

Detection of microRNA expression in human peripheral blood microvesicles. PLoS One (2008) 8.04

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53

Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41

Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A (2010) 6.72

Circulating microRNAs in patients with coronary artery disease. Circ Res (2010) 6.28

Characterization of extracellular circulating microRNA. Nucleic Acids Res (2011) 6.24

Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med (2007) 6.01

Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med (2006) 5.49

Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res (2010) 5.08

MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07

Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal (2009) 4.73

Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38

HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ (2009) 4.19

Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology (2012) 3.94

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68

Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23

Haemolysis during sample preparation alters microRNA content of plasma. PLoS One (2011) 2.92

Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92

Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation (2011) 2.60

Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol (2012) 2.59

Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59

Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47

Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (2011) 2.43

Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS (2010) 2.22

Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol (2010) 2.07

Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS (2010) 2.04

Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02

Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol (2010) 2.01

Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol (2012) 1.81

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73

Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J Immunol (2012) 1.71

Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65

Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients. Retrovirology (2012) 1.62

Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil. PLoS One (2008) 1.56

Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. Mol Cell (2012) 1.56

Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev (2009) 1.53

Horizontal transfer of microRNAs: molecular mechanisms and clinical applications. Protein Cell (2012) 1.49

Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate (2012) 1.39

Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS (2013) 1.34

The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS One (2012) 1.31

Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab (2012) 1.31

Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis (2012) 1.24

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23

A plasma microRNA signature of acute lentiviral infection: biomarkers of central nervous system disease. AIDS (2011) 1.10

MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med (2011) 1.01

Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation. PLoS One (2013) 0.94

Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis (2013) 0.93

MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. Sci Rep (2014) 0.93

Cardiovascular extracellular microRNAs: emerging diagnostic markers and mechanisms of cell-to-cell RNA communication. Front Genet (2013) 0.92

MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. PLoS One (2014) 0.92

HIV Tat induces expression of ICAM-1 in HUVECs: implications for miR-221/-222 in HIV-associated cardiomyopathy. PLoS One (2013) 0.92

miRNAs and HIV: unforeseen determinants of host-pathogen interaction. Immunol Rev (2013) 0.90

Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. J Acquir Immune Defic Syndr (2014) 0.85

Ribonuclease activity in human plasma. Clin Biochem (1972) 0.84

Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. AIDS (2012) 0.82

Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. Int J Antimicrob Agents (2006) 0.79

Determination of free haemoglobin in serum by an automated assay using 4-aminophenazone and the Cobas Bio System. J Clin Chem Clin Biochem (1981) 0.76

Letter by Marques and Morris regarding article, "Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection". Circulation (2012) 0.75